Find Systemic Lupus Erythematosus (SLE) Clinical Trials Near You
A Multicenter, Open-Label, Phase II Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
Status: Recruiting
Location: See all (39) locations...
Intervention Type: Combination product
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while on background standard of care (SoC) therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 5
Maximum Age: 17
Healthy Volunteers: f
View:
• Diagnosis of SLE.
• Must be receiving at least one of the following SoC regimens for ≥ 4 weeks: oral glucocorticoids (≤1.0 mg/kg/day or ≤ 40 mg/day prednisone equivalent), antimalarials (hydroxychloroquine, chloroquine, or quinacrine), or a single permitted immunosuppressant (azathioprine, mycophenolate mofetil/mycophenolic acid, methotrexate, mizoribine, or tacrolimus) within specified dose limits.
• Participant must have moderate to severe active SLE disease defined as Systemic lupus erythematosus disease activity index 2000 (SLEDAI-2K) ≥ 6 total points.
• Body weight ≥ 15 kg.
• Participants must agree to follow study specific contraception requirements as per local regulations.
Locations
Other Locations
Australia
Research Site
NOT_YET_RECRUITING
Nedlands
Research Site
NOT_YET_RECRUITING
Parkville
Research Site
NOT_YET_RECRUITING
Southport
Research Site
NOT_YET_RECRUITING
Westmead
Belgium
Research Site
NOT_YET_RECRUITING
Brussels
Research Site
NOT_YET_RECRUITING
Ghent
Research Site
NOT_YET_RECRUITING
Leuven
Research Site
NOT_YET_RECRUITING
Liège
Chile
Research Site
NOT_YET_RECRUITING
Santiago
Research Site
NOT_YET_RECRUITING
Santiago
Research Site
NOT_YET_RECRUITING
Santiago
Israel
Research Site
NOT_YET_RECRUITING
Haifa
Research Site
NOT_YET_RECRUITING
Kfar Saba
Research Site
NOT_YET_RECRUITING
Petah Tikva
Research Site
NOT_YET_RECRUITING
Ramat Gan
Research Site
NOT_YET_RECRUITING
Tel Aviv
Japan
Research Site
NOT_YET_RECRUITING
Ginowan-shi
Research Site
NOT_YET_RECRUITING
Kagoshima
Research Site
NOT_YET_RECRUITING
Kanazawa
Research Site
NOT_YET_RECRUITING
Niigata
Research Site
NOT_YET_RECRUITING
Setagaya-ku
Netherlands
Research Site
NOT_YET_RECRUITING
Amsterdam
Research Site
NOT_YET_RECRUITING
Rotterdam
Research Site
NOT_YET_RECRUITING
Utrecht
Peru
Research Site
NOT_YET_RECRUITING
Lima
Research Site
NOT_YET_RECRUITING
Lima
Research Site
NOT_YET_RECRUITING
Lima
Research Site
NOT_YET_RECRUITING
Lima
Philippines
Research Site
NOT_YET_RECRUITING
Cebu City
Research Site
NOT_YET_RECRUITING
Dagupan
Research Site
NOT_YET_RECRUITING
Davao City
Research Site
NOT_YET_RECRUITING
Manila
Research Site
NOT_YET_RECRUITING
Manila
Portugal
Research Site
NOT_YET_RECRUITING
Lisbon
Research Site
NOT_YET_RECRUITING
Lisbon
Research Site
NOT_YET_RECRUITING
Porto
Research Site
NOT_YET_RECRUITING
Porto
Serbia
Research Site
RECRUITING
Belgrade
Research Site
RECRUITING
Niš
Contact Information
Primary
AstraZeneca Clinical Study Information Center
information.center@astrazeneca.com
1-877-240-9479
Time Frame
Start Date:2026-08-31
Estimated Completion Date:2031-09-05
Participants
Target number of participants:24
Treatments
Experimental: Cohort 1 (body weight > 40 kg)
Participants with body weight \> 40 kg will receive anifrolumab as an injection in APFS.
Experimental: Cohort 2 (body weight ≥ 15 to ≤ 40 kg)
Participants with body weight ≥ 15 to ≤ 40 kg will receive anifrolumab as an injection in APFS.